Aligos Therapeutics on Track to Complete Phase 2-Enabling Activities in 2023 for its Clinically Validated THR-ß Drug Candidate for NASH, ALG-055009

– Final cohort of Phase 1 study projected to be complete in H1 2023 –

– Phase 2-enabling GLP toxicology studies projected to be complete in H2 2023 –

– Clinical update on all pipeline programs to be presented at the 2023 J.P. Morgan Healthcare Conference on January 12 at 10:30 a.m. PT –

Excerpt from the Press Release:

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases, today announced that the company remains on track to complete all Phase 2-enabling activities in 2023 for ALG-055009, its thyroid hormone receptor beta (THR-ß) drug candidate for nonalcoholic steatohepatitis (NASH).

“Initial Phase 1 clinical data demonstrate that ALG-055009 is favorably differentiated compared to frontrunner THR-ß drug candidates such as resmetirom,” said Lawrence Blatt, Ph.D., MBA, CEO and Chairman of the Board at Aligos. “The dose-proportional pharmacokinetics (PK) and low variability observed with ALG-055009 indicate that, compared to other THR-ß drugs, more predictable and consistent ALG-055009 exposures may be achieved across diverse patient populations. This, in turn, may result in more consistent, and potentially greater, pharmacodynamic effects. The planned upcoming Phase 2 study of ALG-055009 will be important in assessing the spectrum of activity of this molecule. We look forward to elaborating on this and the rest of our pipeline during our presentation at the upcoming JP Morgan conference in San Francisco.”

Matthew W. McClure, M.D., Chief Medical Officer at Aligos Therapeutics, added, “We are enthusiastic about the therapeutic profile of ALG-055009 compared to earlier generation THR-ß drug candidates. Our team is therefore focused on advancing ALG-055009 into Phase 2 as quickly as possible. We anticipate completing the final cohort of the Phase 1 study (NCT05090111) in H1 2023 where the relative bioavailability of the Phase 2 drug formulation will be assessed.

Click the button below to read the entire Press Release:

Continue Reading The Press Release